A Phase 1 interventional study of PfSPZ Vaccine and Normal Saline in Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Tanzania. Open to participants aged 6 Months to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.
Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Malaria by Sanaria Inc. — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Sanaria Inc..
Among the 27 studies in Malaria by Sanaria Inc., this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 20 in phase 1, and was the 12th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →3 of the 27 studies in Malaria by Sanaria Inc. are open now, in 3 countries. Recruiting first, the newest first:
Sanaria Inc. · Sites in Mali
Ages 18–38 · Women only · Healthy volunteers
Sanaria Inc. · Sites in Burkina Faso
Ages 18–50 · Healthy volunteers
Sanaria Inc. · Sites in Germany
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 6 Months to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 7
First in 2010; this study’s year is marked. 2 started in 2015.
This study's enrollment of 105 is below the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 67 across the 27 interventional studies. Of the 24 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanaria Inc. is the lead sponsor of 29 studies on the registry; 4 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
2 of the studies in Malaria by Sanaria Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07385287Sanaria Inc.Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults | 2027-02 |
| NCT06862453Sanaria Inc.Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults | 2027-08-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Malaria by Sanaria Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present trial will evaluate safety and tolerability as well as the vaccine-induced humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and infants who receive doses of 1.8x10\^6, 9.0x10\^5, 4.5x10\^5 or 2.7x10\^5 PfSPZ of PfSPZ Vaccine by direct venous inoculation (DVI),compared with control groups receiving normal saline (NS) placebo by DVI. In addition, as an exploratory objective, controlled human malaria infection (CHMI) will be used to assess efficacy in adults three weeks following immunization.
This is a single center trial to assess the safety, tolerability and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation (DVI) to healthy Tanzanian adults, adolescents, and children and infants. 105 healthy male and female; adults, adolescents, children and infant volunteers, aged from 6 months to 45 years, who live in the Bagamoyo Township will be enrolled based on pre-defined inclusion and exclusion criteria implemented according to international ethical standards.
The safety and tolerability of PfSPZ Vaccine administered as three doses of either 9.0x10\^5 PfSPZ or 1.8x10\^6 PfSPZ to healthy Tanzanian adults, adolescents, and children 6 years of age or older; and three doses of 4.5x10\^5 PfSPZ or 9.0x10\^5 PfSPZ to healthy Tanzanian children 1 to 5 years of age and infants 6 to 11 months of age, in each case compared to NS controls, will be evaluated. In addition, as an exploratory objective, controlled human malaria infection (CHMI) will be used to assess efficacy in adults three weeks following immunization.
Study Design: This is a single center trial with ten groups (Groups 1a/b: ages 18-45; Group 2a/b: ages 11-17; Group 3a/b: ages 6-10; Group 4a/b: ages 1-5; and Group 5b/c: ages 6months-11 months) each with 6 subjects receiving PfSPZ Vaccine and 3 subjects receiving NS and an eleventh smaller group (Group 5a: ages 6months-11months) with 3 subjects receiving PfSPZ Vaccine; two of these groups (Group 1a/b) contain adult volunteers and will have infectivity controls (CHMI 1 and 2) each having 3 subjects, after the vaccination phase of the study. The adult volunteers will undergo CHMI 3 weeks after the last immunization.
For the first immunization, two volunteers (out of six) in Group 1a will receive 9x10\^5 of PfSPZ Vaccine by DVI as sentinels, to demonstrate safety and tolerability. At the same time, one (out of three) corresponding control volunteers will receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 1a will also receive a 9x10\^5 PfSPZ dose of the vaccine and the remaining two placebo recipients will receive NS.
After review of at least +14 days post vaccination safety data for Group 1a by the SMC, if there are no significant safety concerns, two volunteers (out of six) in Group 1b will receive 1.8x10\^6 PfSPZ, and two volunteers (out of six) in each of the Groups 2a and 3a will receive 9x10\^5 PfSPZ, of the PfSPZ Vaccine, to demonstrate safety and tolerability, and each of these sentinel groups will be joined by one corresponding NS control in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 1b will receive 1.8x10\^6 PfSPZ and the remaining four volunteers in each of Groups 2a and 3a will receive 9x10\^5 PfSPZ of the PfSPZ Vaccine, and the remaining placebo recipients will receive NS.
After review of at least +14 days post vaccination safety data for Groups 1b, 2a and 3a by the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of the Groups 2b and 3b will receive 1.8x10\^6 PfSPZ, those in Group 4a will receive 4.5x10\^5 PfSPZ and all 3 volunteers in Group 5a will receive 2.7x10\^5 PfSPZ of PfSPZ Vaccine, to demonstrate safety and tolerability, and each of the sentinel groups (two volunteers from Groups 2b, 3b and 4a) will be joined by one NS control in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Groups 2b, 3b and 4a will receive their appropriate dose of PfSPZ Vaccine (1.8x10\^6 PfSPZ, 1.8x10\^6 PfSPZ, and 4.5x10\^5 PfSPZ, respectively), and the placebo recipients will receive NS.
Escalation from the small group of infants, (Group 5a, n=3) receiving a single dose of 2.7x10\^5 PfSPZ, to the full group (Group 5b, n=6) receiving three doses of 4.5x10\^5 PfSPZ, will proceed without SMC review if criteria for calling an ad hoc SMC meeting are not met. However, if the criteria are met, an ad hoc SMC meeting will be called to review the data, and dose escalation to 4.5x10\^5 PfSPZ will be postponed until the recommendations of the SMC are available. The interval between the 2.7x10\^5 PfSPZ small group and the 4.5x10\^5 PfSPZ larger group will be a minimum of three days.
After review of at least +14 days post vaccination, safety data for Groups 2b, 3b, 4a, 5a and 5b by the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of the Groups 4b and 5c will receive 9x10\^5 PfSPZ, to demonstrate safety and tolerability. At the same time, one (out of three) corresponding control volunteers will receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 4b and 5c will receive 9x10\^5 PfSPZ dose of the vaccine, and the placebo recipients will receive NS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
18- 45 years; n=6; 3 doses of 9 x 10\^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (for CHMI)
18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
Other: Normal Saline · Biological: PfSPZ Challenge (for CHMI)
18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
Biological: PfSPZ Challenge (for CHMI)
18- 45 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (for CHMI)
18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
Other: Normal Saline · Biological: PfSPZ Challenge (for CHMI)
18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
Biological: PfSPZ Challenge (for CHMI)
11-17 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
11-17 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
6-10 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
6-10 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
1-5 years; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
1-5 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
6-11 months; n=3; 1 dose of 2.7 x 10\^5 PfSPZ Vaccine.
Biological: PfSPZ Vaccine
6-11 months; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
6-11 months; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
Biological: PfSPZ Vaccine
6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
Other: Normal Saline
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
0.9% Sodium chloride
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Incidence and type of Adverse Events
Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards. 1. Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination) 2. Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination. 3. Occurrence of serious adverse events during the study period. 4. Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).
Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization
Level of Antibodies against Pf proteins in volunteer sera
1. Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens\[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1\] by ELISA 2. Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA. 3. Analysis of antibodies to proteins in the Pf proteome array chip.
Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization
Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes
Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay
Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization
Quantitation of cellular immune responses against Pf proteins in volunteers
1. Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines. 2. Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.
Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization
Whole genome expression profiles of volunteer
Human gene expression profiling focusing on immune response genes in volunteers
Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization
Number of adult volunteers protected against CHMI following immunization
Evidence of vaccine-mediated protection against CHMI 3 weeks after last immunization in Groups 1 (adults) by preventing blood stage infection for 28 days (as detected by blood smear analysis and qPCR) following CHMI.
Time frame: 28 days post CHMI
Genetic profiles of Pf parasites
Whole genome sequencing of Plasmodium falciparum following break through infections.
Time frame: Screening uptil 56 days post-CHMI or 56 days post-3rd immunization
Ran from Dec 2015 to primary completion in Feb 2017, 14 months.
Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 14 months is above that.
Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.